Inceptionr LLC Sells 15,928 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Inceptionr LLC decreased its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 27.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 41,921 shares of the company’s stock after selling 15,928 shares during the quarter. Inceptionr LLC’s holdings in Amneal Pharmaceuticals were worth $332,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Gladius Capital Management LP purchased a new stake in Amneal Pharmaceuticals during the 3rd quarter worth about $37,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Amneal Pharmaceuticals during the 4th quarter worth about $81,000. Quest Partners LLC purchased a new stake in Amneal Pharmaceuticals during the 3rd quarter worth about $84,000. Janney Montgomery Scott LLC purchased a new stake in Amneal Pharmaceuticals during the 4th quarter worth about $121,000. Finally, Quadrature Capital Ltd purchased a new stake in Amneal Pharmaceuticals during the 3rd quarter worth about $169,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Up 1.6 %

Shares of NASDAQ AMRX opened at $8.90 on Monday. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of -13.09 and a beta of 1.05. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.18 and a 1-year high of $9.48. The stock’s 50-day moving average is $8.20 and its 200 day moving average is $8.35.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). The firm had revenue of $730.52 million for the quarter, compared to analysts’ expectations of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same period in the prior year, the business posted $0.14 earnings per share. On average, analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 62,590 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $8.01, for a total transaction of $501,345.90. Following the transaction, the director now directly owns 1,968,886 shares of the company’s stock, valued at approximately $15,770,776.86. This trade represents a 3.08 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last three months, insiders have sold 240,000 shares of company stock valued at $2,004,000. Corporate insiders own 26.56% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on AMRX shares. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $9.00 to $12.00 in a report on Monday, February 24th. StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Barclays raised their price target on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, March 3rd. Finally, Piper Sandler raised their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $10.80.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.